CN1328148A - 一种新的多肽——人蛋白磷酸酶9.68和编码这种多肽的多核苷酸 - Google Patents

一种新的多肽——人蛋白磷酸酶9.68和编码这种多肽的多核苷酸 Download PDF

Info

Publication number: CN1328148A
Authority: CN; China
Prior art keywords: polynucleotide; polypeptide; human protein; sequence; protein phosphatase
Prior art date: 2000-06-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CN 00116488

Other languages

English (en)

Chinese (zh)

Inventor

毛裕民

谢毅

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Shanghai Biowindow Gene Development Inc

Original Assignee

Shanghai Biowindow Gene Development Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-14

Filing date

2000-06-14

Publication date

2001-12-26

2000-06-14 Application filed by Shanghai Biowindow Gene Development Inc filed Critical Shanghai Biowindow Gene Development Inc

2000-06-14 Priority to CN 00116488 priority Critical patent/CN1328148A/zh

2001-06-11 Priority to AU89542/01A priority patent/AU8954201A/en

2001-06-11 Priority to PCT/CN2001/000962 priority patent/WO2002000834A2/fr

2001-12-26 Publication of CN1328148A publication Critical patent/CN1328148A/zh

Status Pending legal-status Critical Current

Links

102000040430 polynucleotide Human genes 0.000 title claims abstract description 114
108091033319 polynucleotide Proteins 0.000 title claims abstract description 114
239000002157 polynucleotide Substances 0.000 title claims abstract description 114
108700019535 Phosphoprotein Phosphatases Proteins 0.000 title claims abstract description 31
102000045595 Phosphoprotein Phosphatases Human genes 0.000 title claims abstract description 31
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 114
229920001184 polypeptide Polymers 0.000 claims abstract description 108
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 107
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 27
201000010099 disease Diseases 0.000 claims abstract description 26
239000005557 antagonist Substances 0.000 claims abstract description 18
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims description 102
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims description 102
108090000144 Human Proteins Proteins 0.000 claims description 99
102000003839 Human Proteins Human genes 0.000 claims description 99
238000000034 method Methods 0.000 claims description 81
108090000623 proteins and genes Proteins 0.000 claims description 73
239000000523 sample Substances 0.000 claims description 71
238000009396 hybridization Methods 0.000 claims description 37
230000014509 gene expression Effects 0.000 claims description 31
239000002773 nucleotide Substances 0.000 claims description 31
125000003729 nucleotide group Chemical group 0.000 claims description 31
239000012634 fragment Substances 0.000 claims description 30
150000007523 nucleic acids Chemical class 0.000 claims description 24
150000001875 compounds Chemical class 0.000 claims description 21
102000039446 nucleic acids Human genes 0.000 claims description 18
108020004707 nucleic acids Proteins 0.000 claims description 18
230000000295 complement effect Effects 0.000 claims description 15
201000011510 cancer Diseases 0.000 claims description 13
239000013604 expression vector Substances 0.000 claims description 13
239000013598 vector Substances 0.000 claims description 12
230000000694 effects Effects 0.000 claims description 11
239000013612 plasmid Substances 0.000 claims description 11
239000000556 agonist Substances 0.000 claims description 10
238000006243 chemical reaction Methods 0.000 claims description 10
239000003814 drug Substances 0.000 claims description 9
238000002360 preparation method Methods 0.000 claims description 8
239000003112 inhibitor Substances 0.000 claims description 7
241000700605 Viruses Species 0.000 claims description 6
230000003321 amplification Effects 0.000 claims description 6
238000003199 nucleic acid amplification method Methods 0.000 claims description 6
230000000692 anti-sense effect Effects 0.000 claims description 5
238000003745 diagnosis Methods 0.000 claims description 5
238000001727 in vivo Methods 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 3
208000026278 immune system disease Diseases 0.000 claims description 3
238000002493 microarray Methods 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
208000031886 HIV Infections Diseases 0.000 claims description 2
208000037357 HIV infectious disease Diseases 0.000 claims description 2
206010061218 Inflammation Diseases 0.000 claims description 2
230000008485 antagonism Effects 0.000 claims description 2
238000013459 approach Methods 0.000 claims description 2
208000022602 disease susceptibility Diseases 0.000 claims description 2
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 2
230000004054 inflammatory process Effects 0.000 claims description 2
238000004088 simulation Methods 0.000 claims description 2
239000003981 vehicle Substances 0.000 claims description 2
125000003275 alpha amino acid group Chemical group 0.000 claims 6
206010028980 Neoplasm Diseases 0.000 abstract description 23
238000004519 manufacturing process Methods 0.000 abstract description 12
206010012559 Developmental delay Diseases 0.000 abstract description 4
230000009471 action Effects 0.000 abstract description 2
238000012270 DNA recombination Methods 0.000 abstract 1
230000013020 embryo development Effects 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 74
108020004414 DNA Proteins 0.000 description 44
150000001413 amino acids Chemical group 0.000 description 40
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 39
239000002299 complementary DNA Substances 0.000 description 30
102000004169 proteins and genes Human genes 0.000 description 30
238000005516 engineering process Methods 0.000 description 29
235000018102 proteins Nutrition 0.000 description 29
210000001519 tissue Anatomy 0.000 description 23
229940024606 amino acid Drugs 0.000 description 21
235000001014 amino acid Nutrition 0.000 description 21
239000000047 product Substances 0.000 description 20
108091028043 Nucleic acid sequence Proteins 0.000 description 19
108091032973 (ribonucleotides)n+m Proteins 0.000 description 18
230000008859 change Effects 0.000 description 18
108091034117 Oligonucleotide Proteins 0.000 description 14
238000003752 polymerase chain reaction Methods 0.000 description 14
208000032170 Congenital Abnormalities Diseases 0.000 description 12
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 12
238000001556 precipitation Methods 0.000 description 11
238000005406 washing Methods 0.000 description 11
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
230000006870 function Effects 0.000 description 10
230000012010 growth Effects 0.000 description 10
235000013372 meat Nutrition 0.000 description 10
108020004999 messenger RNA Proteins 0.000 description 10
241000894006 Bacteria Species 0.000 description 9
206010005003 Bladder cancer Diseases 0.000 description 9
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 9
239000000203 mixture Substances 0.000 description 9
238000000926 separation method Methods 0.000 description 9
238000012360 testing method Methods 0.000 description 9
201000005112 urinary bladder cancer Diseases 0.000 description 9
230000008034 disappearance Effects 0.000 description 8
210000003414 extremity Anatomy 0.000 description 8
230000000505 pernicious effect Effects 0.000 description 8
238000012216 screening Methods 0.000 description 8
239000000243 solution Substances 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
108091026890 Coding region Proteins 0.000 description 7
101000803165 Homo sapiens Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A beta isoform Proteins 0.000 description 7
102000043136 MAP kinase family Human genes 0.000 description 7
108091054455 MAP kinase family Proteins 0.000 description 7
230000033228 biological regulation Effects 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
239000012528 membrane Substances 0.000 description 7
238000001228 spectrum Methods 0.000 description 7
102000004190 Enzymes Human genes 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 6
125000000539 amino acid group Chemical group 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
230000004071 biological effect Effects 0.000 description 6
230000008827 biological function Effects 0.000 description 6
210000000988 bone and bone Anatomy 0.000 description 6
230000022131 cell cycle Effects 0.000 description 6
210000004907 gland Anatomy 0.000 description 6
239000000463 material Substances 0.000 description 6
230000001105 regulatory effect Effects 0.000 description 6
230000008521 reorganization Effects 0.000 description 6
230000008054 signal transmission Effects 0.000 description 6
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 5
102100035547 Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A beta isoform Human genes 0.000 description 5
230000002159 abnormal effect Effects 0.000 description 5
230000002759 chromosomal effect Effects 0.000 description 5
230000008175 fetal development Effects 0.000 description 5
210000002950 fibroblast Anatomy 0.000 description 5
210000004962 mammalian cell Anatomy 0.000 description 5
239000003550 marker Substances 0.000 description 5
238000010369 molecular cloning Methods 0.000 description 5
210000001672 ovary Anatomy 0.000 description 5
108091092562 ribozyme Proteins 0.000 description 5
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 5
210000003932 urinary bladder Anatomy 0.000 description 5
101000741929 Caenorhabditis elegans Serine/threonine-protein phosphatase 2A catalytic subunit Proteins 0.000 description 4
108090000994 Catalytic RNA Proteins 0.000 description 4
102000053642 Catalytic RNA Human genes 0.000 description 4
206010010356 Congenital anomaly Diseases 0.000 description 4
238000000018 DNA microarray Methods 0.000 description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
238000000636 Northern blotting Methods 0.000 description 4
241000283973 Oryctolagus cuniculus Species 0.000 description 4
101150093883 Ppp2r1b gene Proteins 0.000 description 4
239000002671 adjuvant Substances 0.000 description 4
210000004556 brain Anatomy 0.000 description 4
150000001720 carbohydrates Chemical class 0.000 description 4
230000004663 cell proliferation Effects 0.000 description 4
230000030609 dephosphorylation Effects 0.000 description 4
238000006209 dephosphorylation reaction Methods 0.000 description 4
238000001514 detection method Methods 0.000 description 4
238000001035 drying Methods 0.000 description 4
239000003102 growth factor Substances 0.000 description 4
230000001900 immune effect Effects 0.000 description 4
238000007901 in situ hybridization Methods 0.000 description 4
238000003780 insertion Methods 0.000 description 4
230000037431 insertion Effects 0.000 description 4
PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 4
239000007788 liquid Substances 0.000 description 4
230000026731 phosphorylation Effects 0.000 description 4
238000006366 phosphorylation reaction Methods 0.000 description 4
230000001766 physiological effect Effects 0.000 description 4
230000008569 process Effects 0.000 description 4
238000010839 reverse transcription Methods 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
231100000241 scar Toxicity 0.000 description 4
239000000126 substance Substances 0.000 description 4
210000001550 testis Anatomy 0.000 description 4
210000001541 thymus gland Anatomy 0.000 description 4
238000002965 ELISA Methods 0.000 description 3
206010016717 Fistula Diseases 0.000 description 3
241000238631 Hexapoda Species 0.000 description 3
206010027336 Menstruation delayed Diseases 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
239000000020 Nitrocellulose Substances 0.000 description 3
206010060862 Prostate cancer Diseases 0.000 description 3
208000000236 Prostatic Neoplasms Diseases 0.000 description 3
108020005091 Replication Origin Proteins 0.000 description 3
240000004808 Saccharomyces cerevisiae Species 0.000 description 3
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
238000002105 Southern blotting Methods 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000004913 activation Effects 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000000872 buffer Substances 0.000 description 3
239000000969 carrier Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
210000000349 chromosome Anatomy 0.000 description 3
230000004087 circulation Effects 0.000 description 3
238000013016 damping Methods 0.000 description 3
238000009826 distribution Methods 0.000 description 3
210000003527 eukaryotic cell Anatomy 0.000 description 3
230000003890 fistula Effects 0.000 description 3
239000012530 fluid Substances 0.000 description 3
201000004637 gastric cardia carcinoma Diseases 0.000 description 3
238000001415 gene therapy Methods 0.000 description 3
230000002068 genetic effect Effects 0.000 description 3
108060003552 hemocyanin Proteins 0.000 description 3
206010073071 hepatocellular carcinoma Diseases 0.000 description 3
210000003917 human chromosome Anatomy 0.000 description 3
210000004754 hybrid cell Anatomy 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
230000003834 intracellular effect Effects 0.000 description 3
201000007270 liver cancer Diseases 0.000 description 3
208000014018 liver neoplasm Diseases 0.000 description 3
238000013507 mapping Methods 0.000 description 3
210000001370 mediastinum Anatomy 0.000 description 3
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 3
238000002156 mixing Methods 0.000 description 3
210000004400 mucous membrane Anatomy 0.000 description 3
210000003205 muscle Anatomy 0.000 description 3
210000005036 nerve Anatomy 0.000 description 3
229920001220 nitrocellulos Polymers 0.000 description 3
230000008520 organization Effects 0.000 description 3
239000002953 phosphate buffered saline Substances 0.000 description 3
238000000746 purification Methods 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
238000003757 reverse transcription PCR Methods 0.000 description 3
239000001632 sodium acetate Substances 0.000 description 3
229960004249 sodium acetate Drugs 0.000 description 3
235000017281 sodium acetate Nutrition 0.000 description 3
230000017105 transposition Effects 0.000 description 3
241000701161 unidentified adenovirus Species 0.000 description 3
241001430294 unidentified retrovirus Species 0.000 description 3
210000004291 uterus Anatomy 0.000 description 3
208000003200 Adenoma Diseases 0.000 description 2
206010001233 Adenoma benign Diseases 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
206010006187 Breast cancer Diseases 0.000 description 2
208000026310 Breast neoplasm Diseases 0.000 description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
206010009269 Cleft palate Diseases 0.000 description 2
108091033380 Coding strand Proteins 0.000 description 2
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
108010067770 Endopeptidase K Proteins 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
108010025076 Holoenzymes Proteins 0.000 description 2
108010044467 Isoenzymes Proteins 0.000 description 2
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
206010058467 Lung neoplasm malignant Diseases 0.000 description 2
102000004108 Neurotransmitter Receptors Human genes 0.000 description 2
108090000590 Neurotransmitter Receptors Proteins 0.000 description 2
108700026244 Open Reading Frames Proteins 0.000 description 2
238000012408 PCR amplification Methods 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
108091000080 Phosphotransferase Proteins 0.000 description 2
102000001253 Protein Kinase Human genes 0.000 description 2
108010058956 Protein Phosphatase 2 Proteins 0.000 description 2
102000006478 Protein Phosphatase 2 Human genes 0.000 description 2
108091034057 RNA (poly(A)) Proteins 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
208000015634 Rectal Neoplasms Diseases 0.000 description 2
108091081021 Sense strand Proteins 0.000 description 2
229920002684 Sepharose Polymers 0.000 description 2
238000012300 Sequence Analysis Methods 0.000 description 2
230000006044 T cell activation Effects 0.000 description 2
102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
239000000427 antigen Substances 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
230000027455 binding Effects 0.000 description 2
239000012472 biological sample Substances 0.000 description 2
238000001574 biopsy Methods 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
239000001110 calcium chloride Substances 0.000 description 2
229910001628 calcium chloride Inorganic materials 0.000 description 2
244000309466 calf Species 0.000 description 2
238000006555 catalytic reaction Methods 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
238000007385 chemical modification Methods 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
210000000038 chest Anatomy 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
230000014107 chromosome localization Effects 0.000 description 2
238000002405 diagnostic procedure Methods 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
238000000605 extraction Methods 0.000 description 2
239000007850 fluorescent dye Substances 0.000 description 2
238000006062 fragmentation reaction Methods 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
239000011521 glass Substances 0.000 description 2
239000005090 green fluorescent protein Substances 0.000 description 2
230000036571 hydration Effects 0.000 description 2
238000006703 hydration reaction Methods 0.000 description 2
230000003053 immunization Effects 0.000 description 2
230000001965 increasing effect Effects 0.000 description 2
230000008595 infiltration Effects 0.000 description 2
238000001764 infiltration Methods 0.000 description 2
238000009413 insulation Methods 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
229960000310 isoleucine Drugs 0.000 description 2
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
210000001630 jejunum Anatomy 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
210000000867 larynx Anatomy 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
239000002502 liposome Substances 0.000 description 2
238000004811 liquid chromatography Methods 0.000 description 2
230000004807 localization Effects 0.000 description 2
210000003141 lower extremity Anatomy 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
201000005202 lung cancer Diseases 0.000 description 2
208000020816 lung neoplasm Diseases 0.000 description 2
239000012139 lysis buffer Substances 0.000 description 2
201000001441 melanoma Diseases 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
230000002969 morbid Effects 0.000 description 2
230000035772 mutation Effects 0.000 description 2
238000012856 packing Methods 0.000 description 2
208000003154 papilloma Diseases 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
102000020233 phosphotransferase Human genes 0.000 description 2
230000037081 physical activity Effects 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
-1 polyoxyethylene Polymers 0.000 description 2
230000002265 prevention Effects 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
210000001236 prokaryotic cell Anatomy 0.000 description 2
108060006633 protein kinase Proteins 0.000 description 2
230000017854 proteolysis Effects 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
238000003259 recombinant expression Methods 0.000 description 2
206010038038 rectal cancer Diseases 0.000 description 2
201000001275 rectum cancer Diseases 0.000 description 2
108091006091 regulatory enzymes Proteins 0.000 description 2
230000008844 regulatory mechanism Effects 0.000 description 2
238000004062 sedimentation Methods 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
238000012882 sequential analysis Methods 0.000 description 2
210000003625 skull Anatomy 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
230000003595 spectral effect Effects 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
238000010361 transduction Methods 0.000 description 2
230000026683 transduction Effects 0.000 description 2
210000000689 upper leg Anatomy 0.000 description 2
208000012991 uterine carcinoma Diseases 0.000 description 2
235000013311 vegetables Nutrition 0.000 description 2
230000004304 visual acuity Effects 0.000 description 2
238000001262 western blot Methods 0.000 description 2
JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
UZGKAASZIMOAMU-UHFFFAOYSA-N 124177-85-1 Chemical compound NP(=O)=O UZGKAASZIMOAMU-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 1
AFMZNQYNOSEBLP-YGOYTEALSA-N 5-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)-2-prop-2-ynyloxolan-2-yl]pyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(N)=CN1[C@]1(CC#C)O[C@H](CO)[C@@H](O)C1 AFMZNQYNOSEBLP-YGOYTEALSA-N 0.000 description 1
FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
108010013043 Acetylesterase Proteins 0.000 description 1
241000540905 Acnemia Species 0.000 description 1
SHYYAQLDNVHPFT-DLOVCJGASA-N Ala-Asn-Phe Chemical compound C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SHYYAQLDNVHPFT-DLOVCJGASA-N 0.000 description 1
SMCGQGDVTPFXKB-XPUUQOCRSA-N Ala-Gly-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N SMCGQGDVTPFXKB-XPUUQOCRSA-N 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
206010002120 Anal atresia Diseases 0.000 description 1
206010056292 Androgen-Insensitivity Syndrome Diseases 0.000 description 1
108020005544 Antisense RNA Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
GLWFAWNYGWBMOC-SRVKXCTJSA-N Asn-Leu-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O GLWFAWNYGWBMOC-SRVKXCTJSA-N 0.000 description 1
UMHUHHJMEXNSIV-CIUDSAMLSA-N Asp-Leu-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O UMHUHHJMEXNSIV-CIUDSAMLSA-N 0.000 description 1
BJDHEININLSZOT-KKUMJFAQSA-N Asp-Tyr-Lys Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(O)=O BJDHEININLSZOT-KKUMJFAQSA-N 0.000 description 1
206010003598 Atelectasis Diseases 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
206010004272 Benign hydatidiform mole Diseases 0.000 description 1
244000025254 Cannabis sativa Species 0.000 description 1
206010007747 Cataract congenital Diseases 0.000 description 1
208000006332 Choriocarcinoma Diseases 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
206010010317 Congenital absence of bile ducts Diseases 0.000 description 1
208000026372 Congenital cystic kidney disease Diseases 0.000 description 1
206010068321 Congenital inguinal hernia Diseases 0.000 description 1
206010011498 Cryptorchism Diseases 0.000 description 1
206010011732 Cyst Diseases 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
206010011882 Deafness congenital Diseases 0.000 description 1
206010061619 Deformity Diseases 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
108010053187 Diphtheria Toxin Proteins 0.000 description 1
102000016607 Diphtheria Toxin Human genes 0.000 description 1
208000027877 Disorders of Sex Development Diseases 0.000 description 1
206010013554 Diverticulum Diseases 0.000 description 1
206010013613 Double ureter Diseases 0.000 description 1
208000007033 Dysgerminoma Diseases 0.000 description 1
201000009051 Embryonal Carcinoma Diseases 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
102000004533 Endonucleases Human genes 0.000 description 1
241000305071 Enterobacterales Species 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
241000975394 Evechinus chloroticus Species 0.000 description 1
206010053717 Fibrous histiocytoma Diseases 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
206010061159 Foot deformity Diseases 0.000 description 1
206010017577 Gait disturbance Diseases 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
208000007569 Giant Cell Tumors Diseases 0.000 description 1
208000032612 Glial tumor Diseases 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
JHSRJMUJOGLIHK-GUBZILKMSA-N Glu-Met-Glu Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)O)N JHSRJMUJOGLIHK-GUBZILKMSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
YTSVAIMKVLZUDU-YUMQZZPRSA-N Gly-Leu-Asp Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O YTSVAIMKVLZUDU-YUMQZZPRSA-N 0.000 description 1
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
208000006358 Hand Deformities Diseases 0.000 description 1
101000829958 Homo sapiens N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase Proteins 0.000 description 1
208000000203 Hyaline Membrane Disease Diseases 0.000 description 1
208000006937 Hydatidiform mole Diseases 0.000 description 1
KOPIAUWNLKKELG-SIGLWIIPSA-N Ile-His-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N KOPIAUWNLKKELG-SIGLWIIPSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
208000032571 Infant acute respiratory distress syndrome Diseases 0.000 description 1
208000035478 Interatrial communication Diseases 0.000 description 1
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
241000880493 Leptailurus serval Species 0.000 description 1
QNBVTHNJGCOVFA-AVGNSLFASA-N Leu-Leu-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCC(O)=O QNBVTHNJGCOVFA-AVGNSLFASA-N 0.000 description 1
UBZGNBKMIJHOHL-BZSNNMDCSA-N Leu-Leu-Phe Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C([O-])=O)CC1=CC=CC=C1 UBZGNBKMIJHOHL-BZSNNMDCSA-N 0.000 description 1
IEWBEPKLKUXQBU-VOAKCMCISA-N Leu-Leu-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IEWBEPKLKUXQBU-VOAKCMCISA-N 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
XABXVVSWUVCZST-GVXVVHGQSA-N Lys-Val-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN XABXVVSWUVCZST-GVXVVHGQSA-N 0.000 description 1
208000000172 Medulloblastoma Diseases 0.000 description 1
206010027406 Mesothelioma Diseases 0.000 description 1
SOAYQFDWEIWPPR-IHRRRGAJSA-N Met-Ser-Tyr Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O SOAYQFDWEIWPPR-IHRRRGAJSA-N 0.000 description 1
208000009795 Microphthalmos Diseases 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
CZCIKBSVHDNIDH-NSHDSACASA-N N(alpha)-methyl-L-tryptophan Chemical compound C1=CC=C2C(C[C@H]([NH2+]C)C([O-])=O)=CNC2=C1 CZCIKBSVHDNIDH-NSHDSACASA-N 0.000 description 1
XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
102100023315 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase Human genes 0.000 description 1
125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
CZCIKBSVHDNIDH-UHFFFAOYSA-N Nalpha-methyl-DL-tryptophan Natural products C1=CC=C2C(CC(NC)C(O)=O)=CNC2=C1 CZCIKBSVHDNIDH-UHFFFAOYSA-N 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
206010028974 Neonatal respiratory distress syndrome Diseases 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
208000008846 Neurocytoma Diseases 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
208000008701 Ovotesticular Disorders of Sex Development Diseases 0.000 description 1
206010070872 Persistent pupillary membrane Diseases 0.000 description 1
VDTYRPWRWRCROL-UFYCRDLUSA-N Phe-Val-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 VDTYRPWRWRCROL-UFYCRDLUSA-N 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
STASJMBVVHNWCG-IHRRRGAJSA-N Pro-His-Leu Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C([O-])=O)NC(=O)[C@H]1[NH2+]CCC1)C1=CN=CN1 STASJMBVVHNWCG-IHRRRGAJSA-N 0.000 description 1
VDHGTOHMHHQSKG-JYJNAYRXSA-N Pro-Val-Phe Chemical compound CC(C)[C@H](NC(=O)[C@@H]1CCCN1)C(=O)N[C@@H](Cc1ccccc1)C(O)=O VDHGTOHMHHQSKG-JYJNAYRXSA-N 0.000 description 1
241000125945 Protoparvovirus Species 0.000 description 1
201000005613 Pseudohermaphroditism Diseases 0.000 description 1
208000007123 Pulmonary Atelectasis Diseases 0.000 description 1
108010039491 Ricin Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
BFDMCHRDSYTOLE-UHFFFAOYSA-N SC#N.NC(N)=N.ClC(Cl)Cl.OC1=CC=CC=C1 Chemical compound SC#N.NC(N)=N.ClC(Cl)Cl.OC1=CC=CC=C1 BFDMCHRDSYTOLE-UHFFFAOYSA-N 0.000 description 1
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
DSSOYPJWSWFOLK-CIUDSAMLSA-N Ser-Cys-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(O)=O DSSOYPJWSWFOLK-CIUDSAMLSA-N 0.000 description 1
MOVJSUIKUNCVMG-ZLUOBGJFSA-N Ser-Cys-Ser Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)O)N)O MOVJSUIKUNCVMG-ZLUOBGJFSA-N 0.000 description 1
ULVMNZOKDBHKKI-ACZMJKKPSA-N Ser-Gln-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O ULVMNZOKDBHKKI-ACZMJKKPSA-N 0.000 description 1
VMLONWHIORGALA-SRVKXCTJSA-N Ser-Leu-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]([NH3+])CO VMLONWHIORGALA-SRVKXCTJSA-N 0.000 description 1
FZXOPYUEQGDGMS-ACZMJKKPSA-N Ser-Ser-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O FZXOPYUEQGDGMS-ACZMJKKPSA-N 0.000 description 1
241000187747 Streptomyces Species 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
206010043101 Talipes Diseases 0.000 description 1
206010043276 Teratoma Diseases 0.000 description 1
108700007696 Tetrahydrofolate Dehydrogenase Proteins 0.000 description 1
MROIJTGJGIDEEJ-RCWTZXSCSA-N Thr-Pro-Pro Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 MROIJTGJGIDEEJ-RCWTZXSCSA-N 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
206010051320 Thyroglossal cyst Diseases 0.000 description 1
206010044310 Tracheo-oesophageal fistula Diseases 0.000 description 1
208000005864 Tracheoesophageal Fistula Diseases 0.000 description 1
108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
239000006035 Tryptophane Substances 0.000 description 1
QYSBJAUCUKHSLU-JYJNAYRXSA-N Tyr-Arg-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O QYSBJAUCUKHSLU-JYJNAYRXSA-N 0.000 description 1
206010046879 Vaginal atresia Diseases 0.000 description 1
GQMNEJMFMCJJTD-NHCYSSNCSA-N Val-Pro-Gln Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O GQMNEJMFMCJJTD-NHCYSSNCSA-N 0.000 description 1
208000001910 Ventricular Heart Septal Defects Diseases 0.000 description 1
239000012190 activator Substances 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
238000005377 adsorption chromatography Methods 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
239000005030 aluminium foil Substances 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
210000001909 alveolar process Anatomy 0.000 description 1
238000003277 amino acid sequence analysis Methods 0.000 description 1
206010002320 anencephaly Diseases 0.000 description 1
210000003423 ankle Anatomy 0.000 description 1
208000010133 annular pancreas Diseases 0.000 description 1
230000002788 anti-peptide Effects 0.000 description 1
210000000709 aorta Anatomy 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
108010047857 aspartylglycine Proteins 0.000 description 1
208000013914 atrial heart septal defect Diseases 0.000 description 1
206010003664 atrial septal defect Diseases 0.000 description 1
230000008901 benefit Effects 0.000 description 1
208000001119 benign fibrous histiocytoma Diseases 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
201000005271 biliary atresia Diseases 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
238000011953 bioanalysis Methods 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
210000004958 brain cell Anatomy 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
210000000845 cartilage Anatomy 0.000 description 1
230000005754 cellular signaling Effects 0.000 description 1
210000001638 cerebellum Anatomy 0.000 description 1
239000012295 chemical reaction liquid Substances 0.000 description 1
206010009259 cleft lip Diseases 0.000 description 1
238000000975 co-precipitation Methods 0.000 description 1
239000003184 complementary RNA Substances 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
238000010276 construction Methods 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
201000000160 cryptorchidism Diseases 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
208000031513 cyst Diseases 0.000 description 1
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000010586 diagram Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
102000004419 dihydrofolate reductase Human genes 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
229940079593 drug Drugs 0.000 description 1
235000013399 edible fruits Nutrition 0.000 description 1
210000002310 elbow joint Anatomy 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
238000010195 expression analysis Methods 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
239000000835 fiber Substances 0.000 description 1
230000004992 fission Effects 0.000 description 1
239000005357 flat glass Substances 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
238000011010 flushing procedure Methods 0.000 description 1
210000000245 forearm Anatomy 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
201000008361 ganglioneuroma Diseases 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
201000007116 gestational trophoblastic neoplasm Diseases 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229960002989 glutamic acid Drugs 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
230000036449 good health Effects 0.000 description 1
ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 1
ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
230000002607 hemopoietic effect Effects 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
235000014304 histidine Nutrition 0.000 description 1
125000000487 histidyl group Chemical class [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
108010085325 histidylproline Proteins 0.000 description 1
210000002758 humerus Anatomy 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
208000003906 hydrocephalus Diseases 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
238000003364 immunohistochemistry Methods 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
230000002637 immunotoxin Effects 0.000 description 1
239000002596 immunotoxin Substances 0.000 description 1
231100000608 immunotoxin Toxicity 0.000 description 1
229940051026 immunotoxin Drugs 0.000 description 1
208000002358 imperforate anus Diseases 0.000 description 1
230000008676 import Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
208000016274 isolated tracheo-esophageal fistula Diseases 0.000 description 1
238000002955 isolation Methods 0.000 description 1
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
230000000155 isotopic effect Effects 0.000 description 1
210000003127 knee Anatomy 0.000 description 1
108010030617 leucyl-phenylalanyl-valine Proteins 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
210000005228 liver tissue Anatomy 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
210000001365 lymphatic vessel Anatomy 0.000 description 1
230000000998 lymphohematopoietic effect Effects 0.000 description 1
238000010841 mRNA extraction Methods 0.000 description 1
230000036244 malformation Effects 0.000 description 1
210000005075 mammary gland Anatomy 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
230000013011 mating Effects 0.000 description 1
238000010297 mechanical methods and process Methods 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
208000004840 megacolon Diseases 0.000 description 1
210000002418 meninge Anatomy 0.000 description 1
206010027191 meningioma Diseases 0.000 description 1
210000000713 mesentery Anatomy 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000031864 metaphase Effects 0.000 description 1
WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
201000010478 microphthalmia Diseases 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
210000001989 nasopharynx Anatomy 0.000 description 1
239000005445 natural material Substances 0.000 description 1
210000003739 neck Anatomy 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
210000004126 nerve fiber Anatomy 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
201000010193 neural tube defect Diseases 0.000 description 1
208000007538 neurilemmoma Diseases 0.000 description 1
201000002652 newborn respiratory distress syndrome Diseases 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
238000007899 nucleic acid hybridization Methods 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
201000010302 ovarian serous cystadenocarcinoma Diseases 0.000 description 1
206010033675 panniculitis Diseases 0.000 description 1
239000002245 particle Substances 0.000 description 1
208000003278 patent ductus arteriosus Diseases 0.000 description 1
239000012071 phase Substances 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
108010073101 phenylalanylleucine Proteins 0.000 description 1
108010073025 phenylalanylphenylalanine Proteins 0.000 description 1
239000003123 plant toxin Substances 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
208000030761 polycystic kidney disease Diseases 0.000 description 1
229920002981 polyvinylidene fluoride Polymers 0.000 description 1
238000012805 post-processing Methods 0.000 description 1
238000003825 pressing Methods 0.000 description 1
230000037452 priming Effects 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
210000001147 pulmonary artery Anatomy 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
208000009138 pulmonary valve stenosis Diseases 0.000 description 1
208000030390 pulmonic stenosis Diseases 0.000 description 1
238000000197 pyrolysis Methods 0.000 description 1
238000012797 qualification Methods 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
238000003156 radioimmunoprecipitation Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000004153 renaturation Methods 0.000 description 1
210000004994 reproductive system Anatomy 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
230000004044 response Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
239000002342 ribonucleoside Substances 0.000 description 1
230000000630 rising effect Effects 0.000 description 1
210000000954 sacrococcygeal region Anatomy 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
206010039667 schwannoma Diseases 0.000 description 1
238000007789 sealing Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
208000005893 serous cystadenoma Diseases 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000007781 signaling event Effects 0.000 description 1
239000010703 silicon Substances 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
210000001082 somatic cell Anatomy 0.000 description 1
241000894007 species Species 0.000 description 1
238000010183 spectrum analysis Methods 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
206010041823 squamous cell carcinoma Diseases 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
210000001258 synovial membrane Anatomy 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
229910052714 tellurium Inorganic materials 0.000 description 1
PORWMNRCUJJQNO-UHFFFAOYSA-N tellurium atom Chemical compound [Te] PORWMNRCUJJQNO-UHFFFAOYSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
238000001890 transfection Methods 0.000 description 1
238000003151 transfection method Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
230000014621 translational initiation Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
229940038773 trisodium citrate Drugs 0.000 description 1
208000013327 true hermaphroditism Diseases 0.000 description 1
229960004799 tryptophan Drugs 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
238000002525 ultrasonication Methods 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
210000001364 upper extremity Anatomy 0.000 description 1
210000003708 urethra Anatomy 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
210000003741 urothelium Anatomy 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
201000003130 ventricular septal defect Diseases 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
210000001835 viscera Anatomy 0.000 description 1
210000000707 wrist Anatomy 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1

Images

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)

Landscapes

Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Enzymes And Modification Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

CN 00116488 2000-06-14 2000-06-14 一种新的多肽——人蛋白磷酸酶9.68和编码这种多肽的多核苷酸 Pending CN1328148A (zh)

Priority Applications (3)

Application Number	Priority Date	Filing Date	Title
CN 00116488 CN1328148A (zh)	2000-06-14	2000-06-14	一种新的多肽——人蛋白磷酸酶9.68和编码这种多肽的多核苷酸
AU89542/01A AU8954201A (en)	2000-06-14	2001-06-11	A novel polypeptide, a human phosphatase protein 9.68 and the polynucleotide encoding the polypeptide
PCT/CN2001/000962 WO2002000834A2 (fr)	2000-06-14	2001-06-11	Nouveau polypeptide, proteine phosphatase humaine 9.68, et polynucleotide codant ce polypeptide

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CN 00116488 CN1328148A (zh)	2000-06-14	2000-06-14	一种新的多肽——人蛋白磷酸酶9.68和编码这种多肽的多核苷酸

Publications (1)

Publication Number	Publication Date
CN1328148A true CN1328148A (zh)	2001-12-26

Family

ID=4585892

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CN 00116488 Pending CN1328148A (zh)	2000-06-14	2000-06-14	一种新的多肽——人蛋白磷酸酶9.68和编码这种多肽的多核苷酸

Country Status (3)

Country	Link
CN (1)	CN1328148A (fr)
AU (1)	AU8954201A (fr)
WO (1)	WO2002000834A2 (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9625179D0 (en) *	1996-12-04	1997-01-22	Ver Nl Kanker Inst	Phosphatase subunit polypeptide

2000
- 2000-06-14 CN CN 00116488 patent/CN1328148A/zh active Pending
2001
- 2001-06-11 AU AU89542/01A patent/AU8954201A/en not_active Abandoned
- 2001-06-11 WO PCT/CN2001/000962 patent/WO2002000834A2/fr not_active Ceased

Also Published As

Publication number	Publication date
AU8954201A (en)	2002-01-08
WO2002000834A2 (fr)	2002-01-03
WO2002000834A3 (fr)	2002-04-18

Publication	Publication Date	Title
CN1331340A (zh)	2002-01-16	一种新的多肽——人拓扑异构酶12.1和编码这种多肽的多核苷酸
CN1331170A (zh)	2002-01-16	一种新的多肽——人Purα蛋白13.31和编码这种多肽的多核苷酸
CN1351054A (zh)	2002-05-29	一种新的多肽——人cd63抗原11.11和编码这种多肽的多核苷酸
CN1326962A (zh)	2001-12-19	一种新的多肽——人cd63抗原14.63和编码这种多肽的多核苷酸
CN1328053A (zh)	2001-12-26	一种新的多肽——人ftsH蛋白16.83和编码这种多肽的多核苷酸
CN1358854A (zh)	2002-07-17	一种新的多肽——人蛋白磷酸酶9.35和编码这种多肽的多核苷酸
CN1331155A (zh)	2002-01-16	一种新的多肽——人肝素结合生长因子受体K－ram9.13和编码这种多肽的多核苷酸
CN1358759A (zh)	2002-07-17	一种新的多肽——人p300/CBP结合因子16.72和编码这种多肽的多核苷酸
CN1328148A (zh)	2001-12-26	一种新的多肽——人蛋白磷酸酶9.68和编码这种多肽的多核苷酸
CN1327061A (zh)	2001-12-19	一种新的多肽——人蛋白磷酸酶8.8和编码这种多肽的多核苷酸
CN1327064A (zh)	2001-12-19	一种新的多肽——人蛋白磷酸酶12.98和编码这种多肽的多核苷酸
CN1358852A (zh)	2002-07-17	一种新的多肽——人蛋白磷酸酶12.76和编码这种多肽的多核苷酸
CN1328155A (zh)	2001-12-26	一种新的多肽——人拓扑异构酶ⅰ9.79和编码这种多肽的多核苷酸
CN1358853A (zh)	2002-07-17	一种新的多肽——人蛋白磷酸酶9.68和编码这种多肽的多核苷酸
CN1340545A (zh)	2002-03-20	一种新的多肽——人乳腺易感基因编码的蛋白68.42和编码这种多肽的多核苷酸
CN1333221A (zh)	2002-01-30	一种新的多肽——人泛素化蛋白稳定蛋白9.02和编码这种多肽的多核苷酸
CN1352287A (zh)	2002-06-05	一种新的多肽——人纹状体富集磷酸酶10.56和编码这种多肽的多核苷酸
CN1331295A (zh)	2002-01-16	一种新的多肽——人DNA聚合酶δ12.65和编码这种多肽的多核苷酸
CN1329080A (zh)	2002-01-02	一种新的多肽——人核苷酸切除修复蛋白16.94和编码这种多肽的多核苷酸
CN1326987A (zh)	2001-12-19	一种新的多肽——UbcH5蛋白11.44和编码这种多肽的多核苷酸
CN1331159A (zh)	2002-01-16	一种新的多肽——人线粒体钙粘蛋白10.12和编码这种多肽的多核苷酸
CN1331330A (zh)	2002-01-16	一种新的多肽——人蛋白磷酸酶12.43和编码这种多肽的多核苷酸
CN1343683A (zh)	2002-04-10	一种新的多肽——人核苷酸切除修复蛋白17.6和编码这种多肽的多核苷酸
CN1329046A (zh)	2002-01-02	一种新的多肽——人乳腺易感基因编码的蛋白11.66和编码这种多肽的多核苷酸
CN1329013A (zh)	2002-01-02	一种新的多肽——人核苷酸切除修复蛋白13.31和编码这种多肽的多核苷酸

Legal Events

Date	Code	Title
2001-12-26	C06	Publication
2001-12-26	PB01	Publication
2004-03-03	C02	Deemed withdrawal of patent application after publication (patent law 2001)
2004-03-03	WD01	Invention patent application deemed withdrawn after publication